Endovascular Treatment for Posterior Circulation Ischemic Stroke Post 1 Day （24 Hours）

NCT07699029 | Recruiting

• 1 other identifier: ETP1-PC
• Study Type: interventional
• Target: 244
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the efficacy and safety of endovascular therapy for posterior circulation ischemic stroke presenting more than 24 hours after symptom onset.

Conditions

Posterior Circulation Ischemic Stroke

Keywords

stroke; Posterior Circulation

Outcome Measures

Primary Outcomes (1)

• Proportion of patients with an mRS score of 0-3 at 90 days

  90days

Secondary Outcomes (9)

• Symptomatic intracranial hemorrhage (sICH) (defined as a worsening of NIHSS by 4 or more points within 24 hours after random treatment, associated with intracranial hemorrhage)

  24hours

• Surgical-related complications

  Post procedure 24hours

• Stroke-related mortality at 90 days

  90days

• EQ-5D-5L scale score at 90 days

  90days

• New onset of stroke within 90 days

  90days

Study Arms (2)

control group

OTHER

Standard pharmacological treatment

Drug: Standard pharmacological treatment

Test group

EXPERIMENTAL

Endovascular treatment combined with standard pharmacological treatment

Procedure: Endovascular treatment combined with standard pharmacological treatment

Interventions

Endovascular treatment combined with standard pharmacological treatment PROCEDURE

Mechanical thrombectomy (stent retriever or aspiration) plus standard medical therapy (antiplatelet, statin, and risk factor control), specifically for posterior circulation stroke with onset \>24 h to ≤14 days.

Test group

Standard pharmacological treatment DRUG

Standard medical therapy: antiplatelet, statin, and vascular risk factor control per stroke guidelines, without endovascular intervention.

control group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years old
• Baseline NIHSS score of 4 or higher, maintained prior to randomization
• Stroke onset or more than 24 hours since the last known good state, but within 14 days
• CTA/MRA/DSA confirmed occlusion of the responsible vessel in basilar artery or intracranial segments of both vertebral arteries (V4)
• Modified Rankin Scale (mRS) score of 0 or 1 pre-stroke
• The subject or their legally authorized representative has signed the informed consent form for the study

You may not qualify if:

• Hemorrhage on CT or MRI
• Based on the judgment of the treating physician, the patient is considered unlikely to benefit from the trial (e.g., advanced dementia, severe pre-stroke disability (mRS ≥ 2), or high risk of early mortality)
• Major comorbidities that may interfere with outcome assessment and follow-up (e.g., severe heart failure, renal failure, etc.).
• Evidence of vascular recanalization prior to randomization
• Uncontrolled seizures at the time of stroke onset, if they interfere with obtaining an accurate baseline NIHSS
• Posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) \< 6 on non-contrast CT or CT angiography source images or MR with diffusion-weighted imaging
• Complete cerebellar infarct with significant mass effect and compression of the fourth ventricle,or bilateral thalamic infarction on CT or MRI
• Baseline platelet count \<50,000/uL
• Severe, persistent hypertension (systolic blood pressure \> 220 mmHg or diastolic blood pressure \> 120 mmHg)
• Known hereditary or acquired bleeding disorders, coagulation factor deficiencies, or recent oral anticoagulant therapy with an International Normalized Ratio (INR) \> 3
• Suspected purulent embolism, with a suspicion of bacterial endocarditis
• Known allergies to iodine, heparin, anesthetics, or other explicit contraindications to the endovascular treatment procedure
• Pregnancy
• Other serious, progressive, or end-stage diseases (as determined by the investigator) or a life expectancy of less than 6 months
• Attempted use of a neurothrombectomy device to remove the clot prior to randomization

Sponsors & Collaborators

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology: lead

Study Sites (1)

Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430000, China

RECRUITING

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Central Study Contacts

Bo Hu, Doctor

CONTACT

13707114863; hubo@mail.hust.edu.cn

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director, Head of Neurology, Principal Investigator, Clinical Professor

Study Record Dates

• First Submitted: July 7, 2026
• First Posted: July 13, 2026
• Study Start: July 16, 2026
• Primary Completion (Estimated): August 1, 2029
• Study Completion (Estimated): August 1, 2030
• Last Updated: July 30, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)